ILM1 Stock Overview
Supplies specialty pharmaceutical drugs primarily in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Medios AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €11.92 |
| 52 Week High | €18.50 |
| 52 Week Low | €9.98 |
| Beta | 1.24 |
| 1 Month Change | -4.49% |
| 3 Month Change | -2.77% |
| 1 Year Change | -16.41% |
| 3 Year Change | -51.15% |
| 5 Year Change | -64.31% |
| Change since IPO | 52.84% |
Recent News & Updates
There May Be Some Bright Spots In Medios' (ETR:ILM1) Earnings
Apr 02
Medios AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 28
Expansion Into Advanced Therapies Will Diversify Revenue Streams And Strengthen Market Position
Mar 14 Integration of Ceban drives synergies, enhancing revenue and net margins through cross-selling and economies of scale.Recent updates
There May Be Some Bright Spots In Medios' (ETR:ILM1) Earnings
Apr 02Medios AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 28Expansion Into Advanced Therapies Will Diversify Revenue Streams And Strengthen Market Position
Mar 14 Integration of Ceban drives synergies, enhancing revenue and net margins through cross-selling and economies of scale.Is It Time To Consider Buying Medios AG (ETR:ILM1)?
Feb 18Medios (ETR:ILM1) Is Posting Promising Earnings But The Good News Doesn’t Stop There
May 21Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly
Aug 19Is Medios AG (ETR:ILM1) Trading At A 39% Discount?
Mar 02Is Medios (ETR:ILM1) Using Too Much Debt?
Nov 27Is It Too Late To Consider Buying Medios AG (ETR:ILM1)?
Oct 21Here's Why Medios (ETR:ILM1) Can Manage Its Debt Responsibly
Aug 12Is Now The Time To Look At Buying Medios AG (ETR:ILM1)?
Jul 07Is Medios (ETR:ILM1) Using Too Much Debt?
Apr 28Here's Why I Think Medios (ETR:ILM1) Is An Interesting Stock
Mar 07What Does Medios AG's (ETR:ILM1) Share Price Indicate?
Feb 08Medios (ETR:ILM1) Has A Pretty Healthy Balance Sheet
Nov 29Is There Now An Opportunity In Medios AG (ETR:ILM1)?
Oct 02Medios AG's (ETR:ILM1) Intrinsic Value Is Potentially 35% Above Its Share Price
Jun 18What Is Medios AG's (ETR:ILM1) Share Price Doing?
May 25Are Medios' (ETR:ILM1) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Bullish: Analysts Just Made A Significant Upgrade To Their Medios AG (ETR:ILM1) Forecasts
Jan 21What You Need To Know About Medios AG's (ETR:ILM1) Investor Composition
Jan 19Is It Time To Consider Buying Medios AG (ETR:ILM1)?
Dec 24Analysts Are Betting On Medios AG (ETR:ILM1) With A Big Upgrade This Week
Dec 09The Medios (ETR:ILM1) Share Price Is Up 128% And Shareholders Are Boasting About It
Dec 08Medios AG's (ETR:ILM1) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Nov 22Shareholder Returns
| ILM1 | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 2.1% | 2.2% | 4.3% |
| 1Y | -16.4% | 31.2% | 10.9% |
Return vs Industry: ILM1 underperformed the German Healthcare industry which returned 31.2% over the past year.
Return vs Market: ILM1 underperformed the German Market which returned 10.9% over the past year.
Price Volatility
| ILM1 volatility | |
|---|---|
| ILM1 Average Weekly Movement | 7.0% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: ILM1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: ILM1's weekly volatility (7%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 712 | Matthias Gaertner | www.medios.ag |
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases.
Medios AG Fundamentals Summary
| ILM1 fundamental statistics | |
|---|---|
| Market cap | €304.03m |
| Earnings (TTM) | €12.55m |
| Revenue (TTM) | €1.88b |
24.2x
P/E Ratio0.2x
P/S RatioIs ILM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILM1 income statement (TTM) | |
|---|---|
| Revenue | €1.88b |
| Cost of Revenue | €1.73b |
| Gross Profit | €150.13m |
| Other Expenses | €137.58m |
| Earnings | €12.55m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | 0.49 |
| Gross Margin | 7.97% |
| Net Profit Margin | 0.67% |
| Debt/Equity Ratio | 39.6% |
How did ILM1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/27 14:34 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medios AG is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charlotte Friedrichs | Berenberg |
| Samuel England | Berenberg |
| Maria Vara Fernández | Bryan Garnier & Co |